Analysts: Salix is one of the most undervalued pharmas
At least that's what analysts at brokerage firm Sterne Agee say. They identified Salix Pharmaceuticals as "heavily skewed to the upside" in front of new data the company will soon release on Xifaxan, its leading drug, and sees the company as a "strong candidate to participate in the ongoing consolidation across the sector."
Salix Pharmaceuticals Now Covered by Analysts at Sterne Agee
The firm set a "buy" rating on the stock. A number of other analysts have also recently weighed in on SLXP.
Salix Pharmaceuticals Receives Average Recommendation of "Hold" from Brokerages
Shares of Salix Pharmaceuticals have received an average recommendation of "Hold" from the eighteen ratings firms that are presently covering the company, Analyst RN reports .
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer,...
Upcoming Events, Shares, Stock Price Updates, Notes Exchange Offer, Clinical Study Results and New Product Launch - Analyst Notes on Salix, Endo, ISIS, IDEXX, and Novo Today, Analysts Review released its analysts' notes regarding Salix Pharmaceuticals, Ltd. , Endo International PLC , ISIS Pharmaceuticals, Inc. , IDEXX Laboratories, Inc. , and Novo ... (more)
Contract Pharma Breaking News
Icon Bioscience Appoints CEO
David S. Tierney, MD has been appointed president and chief executive officer of Icon Bioscience, Inc. Dr. Tierney is an accomplished healthcare executive with significant experience in successfully developing and commercializing drug delivery platforms.
The List: Triangle's largest M&A deals in 2013
The Triangle's five largest deals with known values in 2013 totaled about $6.9 billion, a figure dwarfed by 2012's top five total value of $37.8 billion, which included the blockbuster Duke Energy purchase of Progress Energy.
Should Furiex be an acquisition target for Salix?
With Morrisville's Furiex Pharmaceuticals reportedly seeking a buyer, it only makes sense to consider Raleigh-based Salix Pharmaceuticals as a potential match, according to one investment advisor.